Nephros (NEPH) Q3 2025 earnings summary

Executive summary

• Q3 2025 net revenue rose 35% year-over-year to $4.8 million, marking one of the highest quarters, with strong contributions from all business lines and record programmatic sales.

• Net income for Q3 2025 was $337,000, up 84% from $183,000 in Q3 2024; nine-month net income reached $1.1 million versus a $275,000 loss in the prior year.

• Achieved at least four consecutive profitable quarters, driven by recurring revenue streams, operational discipline, and customer-focused initiatives.

• Launched a PFAS removal solution, expanding into new verticals such as municipalities, dialysis centers, labs, and markets with stringent water quality regulations.

• Maintained strong cash reserves and a debt-free balance sheet, positioning for continued growth and market expansion.

Financial highlights

• Q3 2025 net revenue grew 35% year-over-year to $4.8 million; nine-month net revenue rose 37% to $14.1 million.

• Gross margin was 61% for Q3 2025 and improved to 63% for the nine months, up from 61% in the prior year.

• Q3 2025 net income was $337,000; Adjusted EBITDA was $418,000, up 42% from Q3 2024.

• Net cash provided by operating activities improved to $99,000 in Q3 2025 and $1.4 million for the nine months.

• Cash and cash equivalents stood at $5.2 million as of September 30, 2025, with no debt.

Outlook and guidance

• Management expects continued growth, supported by a robust innovation pipeline, expanded market reach, and investments in product development and customer engagement.

• PFAS and microplastics solutions are expected to drive future growth as regulatory and market awareness increases.

• Gross margins are expected to remain above 60%, with minor fluctuations due to tariffs and business mix.

• Current cash balances are believed sufficient to fund operations for at least the next 12 months.